News Bulletin
Friday, November 13, 2026
Morning Edition
Economic Numbers:
|
Time |
Event |
Actual |
Forecast |
Previous |
|
56m |
|
0.004 |
1.30% |
|
|
56m |
|
0.003 |
0.70% |
|
|
56m |
|
0.066 |
6.30% |
|
|
56m |
|
0.05 |
5.00% |
|
|
56m |
|
|
0.50% |
|
|
56m |
|
|
5.00% |
|
|
10:30 |
|
65B |
77B |
|
|
13:00 |
|
|
46300.00% |
|
|
13:00 |
|
|
60400.00% |
Indices
|
|
CLOSE |
50 DMA |
200 DMA |
|
DJIA |
52,297.09 |
52,000.64 |
50,740.73 |
|
NASDAQ |
25,366.09 |
26,379.03 |
25,130.16 |
|
S&P 500 |
7,592.40 |
7,671.18 |
7,335.42 |
Earnings Calendar:
(EPS: Earning Per Share / Rev: Revenue / Mkt Cap : market Capital/ BMO :
Before Market Opening /AMC : After Market Close)
|
COMPANY |
EPS Act |
EPS
Fore |
Rev
Act |
Rev
Fore |
Mkt Cap |
Fiscal |
Time |
|
$16.31B |
Q3 |
AM |
|||||
|
-- |
-- |
$9.92B |
Q2 |
AM |
|||
|
$6.82B |
Q3 |
AM |
|||||
|
-- |
-- |
$5.60B |
Q3 |
PM |
|||
|
-1.57 |
-698.57M |
$3.94B |
Q1 |
AM |
|||
|
-0.33 |
-998.1M |
$1.53B |
Q3 |
PM |
Market
News:
Here are some of the biggest premarket US stock movers today:
Milestone
Pharmaceuticals Inc. (NASDAQ:MIST) reported third quarter results that
exceeded analyst expectations, driven by stronger-than-expected product revenue
from its recently launched CARDAMYST nasal spray.
The turmoil surrounding Nvidia is
raising questions about more than the future of the world’s most influential AI
chipmaker, with a previously bullish semiconductor analyst warning that the
fallout could spread across the industry through weaker AI investment and
tighter US export restrictions.
Zai Lab Limited (ZLAB) released preliminary first-in-human
results from the single-ascending-dose portion of its Phase 1/1b trial of
ZL-1503, a bispecific antibody targeting IL-13 and
IL-31 receptor alpha, developed for moderate-to-severe atopic dermatitis.
AstraZeneca
(AZN) has received a recommendation for approval of its
drug Baxfendy (baxdrostat)
in the European Union, according to a press release statement.
Dot Ai (Nasdaq: DAIC), has launched an electric vehicle
car-sharing service at Blume on 16th, a 325-bed luxury
student housing community near Ohio State University in Columbus, Ohio.
BioCryst Pharmaceuticals (Nasdaq: BCRX)
presented two real-world studies at the American College of Allergy, Asthma
& Immunology 2026 Annual Scientific Meeting in Phoenix, showing reductions
in healthcare resource utilization among hereditary angioedema
(HAE) patients who initiated or switched to ORLADEYO (berotralstat).
For internal use only